S&P 500
(0.25%) 5 261.38 points
Dow J
(0.21%) 39 845 points
Nasdaq
(-0.02%) 16 397 points
Oil
(2.13%) $83.08
Gas
(1.69%) $1.747
Gold
(1.28%) $2 241.10
Silver
(0.85%) $24.96
Platinum
(1.26%) $921.20
USD/EUR
(0.39%) $0.927
USD/NOK
(0.80%) $10.85
USD/GBP
(0.13%) $0.792
USD/RUB
(0.12%) $92.55

Realtime updates for UCB SA [UCBJY]

Exchange: OTC Sector: Healthcare Industry: Biotechnology
Last Updated28 Mar 2024 @ 14:10

0.12% $ 61.65

Live Chart Being Loaded With Signals

Commentary (28 Mar 2024 @ 14:10):

Warning: Trying to access array offset on null in /home/getagraph/public_html/stock.php on line 302

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies...

Stats
Today's Volume 2 896.00
Average Volume 11 883.00
Market Cap 23.40B
Last Dividend $0.726 ( 2023-05-01 )
Next Dividend $0 ( N/A )
P/E 64.89
ATR14 $0.121 (0.20%)

UCB SA Correlation

10 Most Positive Correlations
10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

UCB SA Financials

Annual 2023
Revenue: $5.25B
Gross Profit: $3.55B (67.50 %)
EPS: $1.810
Q4 2023
Revenue: $2.66B
Gross Profit: $1.65B (62.11 %)
EPS: $0.170
Q2 2023
Revenue: $2.59B
Gross Profit: $1.69B (65.20 %)
EPS: $1.640
Q1 2023
Revenue: $1.26B
Gross Profit: $858.50M (68.16 %)
EPS: $0.800

Financial Reports:

No articles found.

UCB SA Dividends

(Q3/22) (Q4/22) (Q1/23) (Q2/23) (Q3/23) (Q4/23) (Q1/24) (Q2/24) (Q3/24) (Q4/24)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0.726
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)

UCB SA Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 4.49 - Stable (10.24%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information
First Dividend $0.663 2013-05-02
Last Dividend $0.726 2023-05-01
Next Dividend $0 N/A
Payout Date 2023-05-18
Next Payout Date N/A
# dividends 11 --
Total Paid Out $7.46 --
Avg. Dividend % Per Year 0.00% --
Score 3.12 --
Div. Sustainability Score 10.00
Div.Growth Potential Score 4.49
Div. Directional Score 8.37 --
Next Divdend (Est)
(2024-04-01)
$0.745 Estimate 3.13 %
Dividend Stability
0.25 Very Poor
Dividend Score
3.12
Pay Frequency
Annually
Yearly Payout
Year Amount Yield

Warning: Undefined variable $stockPricesArray in /home/getagraph/public_html/stock.php on line 1111

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for OTC

Symbol Title Last dividend Frequency Years Dividend Yearly Dividend Score
VEOEY Ex Dividend Knight 2023-05-05 Annually 0 0.00%
MONDY Ex Dividend Knight 2023-08-24 Semi-Annually 0 0.00%
CTUY Ex Dividend Junior 2023-05-24 Annually 0 0.00%
SMFKY Ex Dividend Knight 2023-09-28 Semi-Annually 0 0.00%
HMLN Ex Dividend Junior 2023-06-13 Annually 0 0.00%
BFLBY Ex Dividend Knight 2023-04-21 Annually 0 0.00%
YATRF Ex Dividend Knight 2023-09-28 Semi-Annually 0 0.00%
OCLDY Ex Dividend Knight 2023-05-24 Semi-Annually 0 0.00%
EBRPY Ex Dividend Knight 2023-06-28 Quarterly 0 0.00%
SZLMY Ex Dividend Junior 2023-05-03 Annually 0 0.00%

Dividend Sustainability Score (DSS)

RatioActual ValueWeightNormalized ValueScoreRange
netProfitMarginTTM0.05681.5008.8610.00[0 - 0.5]
returnOnAssetsTTM0.03331.2008.8910.00[0 - 0.3]
returnOnEquityTTM0.05731.500-0.474-0.712[0.1 - 1]
payoutRatioTTM0.730-1.0002.70-2.70[0 - 1]
currentRatioTTM1.3170.8008.426.73[1 - 3]
quickRatioTTM0.8390.8009.777.81[0.8 - 2.5]
cashRatioTTM0.3291.5009.2810.00[0.2 - 2]
debtRatioTTM0.196-1.5006.74-10.00[0 - 0.6]
interestCoverageTTM3.571.0009.799.79[3 - 30]
operatingCashFlowPerShareTTM7.472.007.5110.00[0 - 30]
freeCashFlowPerShareTTM4.442.007.7810.00[0 - 20]
debtEquityRatioTTM0.338-1.5008.65-10.00[0 - 2.5]
grossProfitMarginTTM0.6451.0002.592.59[0.2 - 0.8]
operatingProfitMarginTTM0.1081.0009.859.85[0.1 - 0.6]
cashFlowToDebtRatioTTM0.4671.0008.528.52[0.2 - 2]
assetTurnoverTTM0.5860.8009.437.54[0.5 - 2]
Total Score12.24

Dividend Growth Score (DGS)

RatioActual ValueWeightNormalized ValueScoreRange
peRatioTTM20.861.0007.990[1 - 100]
returnOnEquityTTM0.05732.50-0.305-0.712[0.1 - 1.5]
freeCashFlowPerShareTTM4.442.008.5210.00[0 - 30]
dividendYielPercentageTTM1.2761.50010.000[0 - 0.4]
operatingCashFlowPerShareTTM7.472.007.5110.00[0 - 30]
payoutRatioTTM0.7301.5002.70-2.70[0 - 1]
pegRatioTTM01.500-3.330[0.5 - 2]
operatingCashFlowSalesRatioTTM0.1561.0008.600[0.1 - 0.5]
Total Score4.49

UCB SA

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; BIMZELX for treating psoriasis, psoriatic arthritis, axial spondyloarthritis, and hidradenitis suppurativa; and dapirolizumab pegol for systemic lupus erythematosus. In addition, the company is involved in developing rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; zilucoplan to treat myasthenia gravis and immune-mediated necrotizing myopathy; staccato alprazolam to treat tereotypical prolonged seizure; Bepranemab to treat Alzheimer's disease; and UCB0599 to treat Parkinson's disease. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, Otsuka, and doc.ai. It operates in the United States, Japan, Germany, rest of Europe, Spain, France, Italy, the United Kingdom, Ireland, China, Belgium, and internationally. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.

About Live Signals

The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.

The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators